Date: 2015-07-02
Type of information: Production agreement
Compound:
Company: Alexion Pharmaceuticals (USA - CT) Lonza (Switzerland)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: production manufacturing
Action mechanism:
Disease:
Details: * On July 2, 2015, Lonza announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth site. This contract is an expansion of an existing manufacturing agreement. This agreement will supplement existing production of Alexion products at multiple Lonza facilities. The expansion of the existing site in Portsmouth, near Boston, will provide valued customers increased access to Lonza’s proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service.
Financial terms:
Latest news:
